Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec and Harvard University to Collaborate

Published: Thursday, October 10, 2013
Last Updated: Thursday, October 10, 2013
Bookmark and Share
The partnership will explore enteroendocrine signals affecting key metabolic pathways.

Evotec AG have announced a second research collaboration, TargetEEM (Enteroendocrine Mechanisms), with the laboratory of Doug Melton, Xander University Professor in the Department of Stem Cell and Regenerative Biology at Harvard University, Harvard Stem Cell Institute Scientific Co-Director and Howard Hughes Medical Institute Investigator. The objective of this collaboration is to identify novel enteroendocrine mechanisms, pathways and signals regulating key metabolic processes that have disease-modifying potential in diabetic patients. Evotec’s first collaboration with the Melton laboratory was focused on beta cell replication.

Type 2 diabetes is a disease affecting several hundred million people worldwide. Although treatment regimes based on insulin and insulin sensitizers are the standard of care and have helped patients tremendously, they are not modifying cause or progression of the disease.

TargetEEM is comprehensive screening effort by Harvard and Evotec designed to systematically search for novel pathways and targets that have the potential to address key pathophysiological mechanisms involved in insulin resistance and energy handling.

The basis of this effort will be disease-relevant animal models as well as unbiased transcriptional and proteomic profiling platforms contributed by both collaboration partners. Harvard and Evotec will collaborate in a highly integrated and fashion and share potential commercial rewards.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “Metabolic diseases and in particular diabetes continue to be on the rise and are not only a serious threat to patients but represent enormous challenges to healthcare systems all over the world. We are very excited about this second collaboration with Doug’s lab. It is designed to break new ground and identify novel enteroendocrine mechanisms with disease-modifying potential.”

“This collaboration between Harvard and Evotec, the second in the field of metabolic disease, benefits from our good working relationship and mutual interest in undertaking a comprehensive effort to elucidate the disease mechanisms that underlie this serious health problem”, added Dr Vivian Berlin, Director Business Development in Harvard’s Office of Technology Development.

Financial details were not disclosed.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec and Harvard Stem Cell Institute form CureMN Collaboration to Advance ALS Research
Strategic partnership established with the Harvard Stem Cell Institute (“HSCI”) to identify compounds that prevent or slow down the loss of motor neurons.
Thursday, September 12, 2013
Evotec AG: New Hormone to Treat Diabetes Published in “Cell”
Harvard University Prof. Doug Melton and his post doc Peng Yi describe the new hormone “betatrophin” that controls beta cell proliferation as potential diabetes treatment.
Friday, April 26, 2013
Evotec Acquires Compound Management Business from Galapagos
Evotec to further strengthen its integrated innovation offering with world-class compound management.
Thursday, June 02, 2011
Scientific News
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Stem Cells Rescue Patients from Mitochondrial Disease
A study led by OHSU researchers has revealed a critical first step in developing a new gene and stem cell regenerative technique for treating patients with mitochondrial disease.
Eco-Friendly Nanobullet to Battle Bacteria
Researchers have developed a method to combat bacteria by engineering nanoscale particles that add the antimicrobial potency of silver to a core of lignin, a ubiquitous substance found in all plant cells.
Blood Stem Cells in a Rush -- Velocity Determines Quality
Acceleration of the G1 phase transit during cell division makes human blood stem cells more powerful.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!